Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • PF-562271 HCl: Precision FAK/Pyk2 Inhibition in Cancer Re...

    2025-12-08

    PF-562271 HCl: Precision FAK/Pyk2 Inhibition in Cancer Research

    Principle and Setup: Leveraging a Best-in-Class FAK/Pyk2 Inhibitor

    In the evolving landscape of cancer research, dissecting signaling networks that drive tumor progression and metastasis is critical for both basic science and therapeutic innovation. Focal adhesion kinase (FAK) and its homolog proline-rich tyrosine kinase 2 (Pyk2) are central to regulating cellular adhesion, migration, and survival. PF-562271 HCl—supplied by APExBIO—represents a gold-standard reagent for researchers investigating these pathways. As a potent, reversible, ATP-competitive FAK inhibitor (IC50 = 1.5 nM) with strong selectivity over Pyk2 (IC50 = 14 nM) and minimal off-target kinase activity, it is uniquely positioned for high-specificity modulation of focal adhesion kinase signaling pathways in both in vitro and in vivo models.

    PF-562271 HCl’s robust selectivity profile not only ensures precise pathway interrogation but also aligns with contemporary cheminformatics-driven library design, where selectivity and target coverage are paramount. As highlighted by Moret et al. (2019), small-molecule libraries that prioritize binding selectivity and broad kinome coverage enable more interpretable, translatable results in chemical genetics and drug discovery workflows.

    Optimized Experimental Workflow: From Compound Handling to Data Acquisition

    1. Compound Preparation and Storage

    • Solubilization: PF-562271 HCl is highly soluble in DMSO (≥26.35 mg/mL with gentle warming) but insoluble in water or ethanol. Prepare concentrated DMSO stocks immediately before use to maintain compound integrity.
    • Storage: Store the solid at -20°C. For solution stability, avoid long-term storage; freshly prepare aliquots for each experiment to prevent degradation or precipitation.

    2. Cell-Based FAK/Pyk2 Inhibition Assays

    • Cell Seeding: Plate adherent cancer cell lines (e.g., MDA-MB-231, A549) at densities optimized for your endpoint (typically 5,000-10,000 cells/well in 96-well format).
    • Dosing: Dilute PF-562271 HCl into culture medium to achieve final concentrations ranging from 0.1 nM to 1 μM, bracketing the reported IC50 values. Maintain DMSO ≤0.1% v/v to avoid solvent toxicity.
    • Incubation: Treat cells for 1–24 hours depending on endpoint (acute phosphorylation inhibition or longer-term proliferation/migration effects).
    • Readouts: Assess FAK phosphorylation at Tyr397 (e.g., by Western blot or ELISA) to confirm on-target activity. For functional assays, measure cell migration (wound healing/transwell), invasion, or viability (MTT/CellTiter-Glo).

    3. In Vivo Tumor Growth Inhibition

    • Model Selection: Employ murine xenograft models of solid tumors (e.g., breast, ovarian, or prostate cancer).
    • Dosing Regimen: Administer PF-562271 HCl orally or intraperitoneally at doses calibrated to achieve plasma concentrations near the tumor EC50 (93 ng/mL as reported in preclinical studies).
    • Endpoints: Monitor tumor growth, metastasis, and FAK phosphorylation in excised tissue to evaluate drug efficacy and pathway engagement.

    Advanced Applications and Comparative Advantages

    PF-562271 HCl’s high selectivity and reversibility unlock a spectrum of advanced use-cases in cancer research and drug discovery:

    • Tumor Microenvironment Modulation: By inhibiting FAK/Pyk2 signaling, PF-562271 HCl disrupts tumor-stroma interactions, immune evasion, and extracellular matrix remodeling—key determinants of metastatic potential. This is corroborated in this analysis, which highlights the inhibitor’s role in overcoming microenvironment-driven therapy resistance.
    • Dissecting FAK/Pyk2 Redundancy: The compound’s ~10-fold selectivity for FAK over Pyk2 enables precise perturbation experiments, allowing researchers to untangle the contributions of each kinase to cancer phenotypes. For example, parallel use with Pyk2-selective inhibitors or siRNA can clarify compensatory mechanisms.
    • Translational Oncology Workflows: PF-562271 HCl supports both high-throughput screens for anti-cancer agents and detailed mechanistic studies, as emphasized in this protocol-driven article. Its compatibility with multiplexed phenotypic assays offers a platform for combinatorial drug testing and resistance profiling, aligning with data-driven small-molecule library design principles (Moret et al., 2019).
    • Benchmarking and Workflow Integration: Compared to older FAK/Pyk2 inhibitors, PF-562271 HCl demonstrates superior nanomolar potency, rapid washout for reversibility studies, and minimal off-target kinase inhibition—attributes validated in both the primary literature and complementary performance analyses.

    Troubleshooting and Optimization Tips

    • Compound Precipitation: If precipitation occurs after dilution, confirm DMSO content is sufficient and that the solution is gently warmed before use. Avoid aqueous/ethanol solvents.
    • Loss of Activity: Use freshly prepared solutions as prolonged storage in solution can lead to degradation and reduced efficacy. Store unused aliquots at -20°C and avoid freeze-thaw cycles.
    • Off-Target Effects: PF-562271 HCl displays >100-fold selectivity for FAK/Pyk2 versus most kinases; however, some cyclin-dependent kinases (CDKs) may be inhibited at high concentrations. Titrate to the lowest effective dose and confirm specificity with rescue or orthogonal approaches.
    • Cell Line Variability: Response to FAK/Pyk2 inhibition can vary by cell type due to differences in kinase expression or pathway redundancy. Include appropriate controls and, when possible, validate findings using genetic knockdown or alternative inhibitors.
    • In Vivo Dosing Optimization: Monitor animal weight and behavior as indicators of toxicity. Adjust dose and administration route to balance efficacy and tolerability, targeting plasma concentrations near the reported EC50 (93 ng/mL) for FAK phosphorylation inhibition in tumor models.

    Future Outlook: Expanding the Utility of PF-562271 HCl

    As the FAK/Pyk2 axis garners increasing attention in oncology and beyond, PF-562271 HCl is poised to remain an indispensable tool. Its profile aligns with emerging trends in rational inhibitor library design, where selectivity and diversity are optimized for both target engagement and translational value (Moret et al., 2019). Researchers are leveraging PF-562271 HCl in combination screens, resistance mechanism mapping, and even in studies of non-cancer pathologies where FAK/Pyk2 signaling is implicated.

    For those seeking to expand their experimental arsenal, a comparison across the literature reveals that PF-562271 HCl’s reversible, ATP-competitive inhibition and robust selectivity set it apart from legacy inhibitors. As detailed in this comprehensive review, its application in both basic research and translational drug discovery continues to drive impactful discoveries. With APExBIO’s commitment to quality and consistency, PF-562271 HCl remains a trusted choice for precision-targeted cancer research.

    References